Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02451163
Other study ID # Fib-CC-2014
Secondary ID
Status Completed
Phase Phase 2
First received May 19, 2015
Last updated April 11, 2016
Start date September 2014
Est. completion date March 2016

Study information

Verified date April 2016
Source Clinical Research Center Kiel GmbH
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

The aim of the study is to measure the effect of wheat polysaccharides on the occurence of common cold (CC) in elderly during a 12-week consumption period.


Description:

The study is conducted in the frame of the collaborative project 'FibeBiotics' (No. 289517) (Fibers as support of the Gut and Immune function of Elderly - From polysaccharide compound to health Claim) within the Seventh Framework Programme (FP7) for Research and Technological Development of the European Union (EU).


Recruitment information / eligibility

Status Completed
Enrollment 247
Est. completion date March 2016
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

- men and postmenopausal women aged = 50

- willingness to abstain as far as possible from food and supplements containing probiotics, prebiotic supplements, other fermented products, supplements containing vitamins and minerals as well as willingness to sustain a low dietary fibre diet for 14 weeks

- written informed consent

Exclusion Criteria:

- subjects currently enrolled in another clinical study

- subjects having finished another clinical study within the last 4 weeks before inclusion

- surgery or intervention requiring general anaesthesia within 2 months before the study

- current symptoms of common infectious diseases (CID) of the airways or other organ systems e.g. gastrointestinal tract

- history of allergic rhinitis, allergic asthma, anaphylactic shock, quincke edema, food allergy (type I allergy)

- allergy or hypersensitivity to any component of the test product (e. g. wheat, corn)

- known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy, immunosuppression)

- active autoimmune diseases

- severe chronic disease (COPD, respiratory insufficiency, cancer, IBD, malabsorption, malnutrition, chronic inflammatory diseases, severe renal, hepatic or cardiac diseases)

- known coeliac disease (gluten enteropathy)

- chronic systemic or chronic topical treatment likely to interfere with evaluation of the study parameters: antiallergic drugs, antibiotics, intestinal or respiratory antiseptics, anti-rheumatics, antiphlogistics (except aspirin or equivalent products preventing from aggregation of platelets or blood clotting) and steroids prescribed in chronic inflammatory diseases (in the last 4 weeks before inclusion)

- diabetes mellitus

- other chronic treatments likely to interfere with study outcome: e.g. laxatives, body weight management and/or medication

- chronic abdominal pain

- bowel movement less than 3 times per week

- subjects, who meet 2 or more Rome III criteria for constipation or who take laxatives on a regular basis

- vegetarian, vegan diet

- eating disorders (e.g. anorexia, bulimia)

- alcohol and drug abuse

- severe neurological, cognitive or psychiatric diseases

- subjects not understanding or speaking fluently German

- legal incapacity

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Dietary Supplement:
wheat polysaccharides
Consumed once daily for 12 weeks.
maltodextrin
Consumed once daily for 12 weeks.

Locations

Country Name City State
Germany Clinical Research Center (CRC) Kiel GmbH Kiel Schleswig-Holstein

Sponsors (3)

Lead Sponsor Collaborator
Clinical Research Center Kiel GmbH BioActor, European Commission

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of common cold (CC) based on Jackson et al. 1958 and physicians diagnosis Occurrence of common cold (= number of subjects affected by at least one common cold episode during intervention) according to self-reporting (questionnaire based on Jackson et al. 1958) and physicians diagnosis. 12 weeks No
Secondary Cumulative severity of common cold episodes Cumulative severity of common cold episodes (= sum of daily symptom scores acc. to Jackson et al. 1958). 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections Phase 3
Completed NCT01944631 - Iota-Carrageenan Nasal Spray in Common Cold Phase 4
Completed NCT01651715 - Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections Phase 1/Phase 2
Completed NCT00963443 - Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold Phase 3
Completed NCT00778648 - Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms N/A
Completed NCT00065715 - Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo) Phase 3
Completed NCT00032500 - Evaluation of Echinacea for the Common Cold Phase 2
Not yet recruiting NCT05070650 - Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold Phase 3
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Not yet recruiting NCT04073511 - Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold N/A
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Terminated NCT01964885 - Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections Phase 3
Completed NCT01277081 - Effect of Paracetamol on the Common Cold Phase 2
Completed NCT01728090 - Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections Phase 4
Completed NCT00405509 - The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years N/A
Completed NCT01033526 - Symptomatic Treatment of Common Cold Symptoms Phase 4
Completed NCT05556148 - Otrivine: Quality of Life (QoL) Impact in a Real-World Setting Phase 4
Terminated NCT03339726 - Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold Phase 2
Completed NCT01361399 - Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold Phase 3
Recruiting NCT05244148 - Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects N/A